SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Hollan, I; Ronda, N; Dessein, P; Agewall, S; Karpouzas, G; Tamargo, J; Niessner, A; Savarese, G; Rosano, G; Kaski, JC; et al. Hollan, I; Ronda, N; Dessein, P; Agewall, S; Karpouzas, G; Tamargo, J; Niessner, A; Savarese, G; Rosano, G; Kaski, JC; Wassmann, S; Meroni, PL (2020) Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother, 6 (2). pp. 104-114. ISSN 2055-6845 https://doi.org/10.1093/ehjcvp/pvz033
SGUL Authors: Kaski, Juan Carlos

[img] Microsoft Word (.docx) Accepted Version
Restricted to Repository staff only until 9 August 2020.
Available under License ["licenses_description_publisher" not defined].

Download (474kB)
[img] PDF (Table and figure) Accepted Version
Restricted to Repository staff only until 9 August 2020.
Available under License ["licenses_description_publisher" not defined].

Download (859kB)

Abstract

Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity, partly due to alterations in lipoprotein quantity, quality and cell cholesterol trafficking. Although cardiovascular disease significantly contributes to mortality excess in RA, cardiovascular prevention has been largely insufficient. Because of limited evidence, optimal strategies for lipid management (LM) in RA have not been determined yet, and recommendations are largely based on expert opinions. In this position paper, we describe abnormalities in lipid metabolism in RA and introduce a new algorithm for estimation of cardiovascular risk (CVR) and LM in RA. The algorithm stratifies patients according to RA-related factors impacting CVR (such as RA activity and severity and medication) and therefore enables a more nuanced approach than other current methods. We propose strategies for monitoring of lipid parameters and treatment of dyslipidemia in RA (including lifestyle, statins and other lipid-modifying therapies, and disease modifying anti-rheumatic drugs). These opinion-based recommendations are meant to facilitate LM in RA until more evidence is available.

Item Type: Article
Additional Information: This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal - Cardiovascular Pharmacotherapy following peer review. The version of record Ivana Hollan, Nicoletta Ronda, Patrick Dessein, Stefan Agewall, George Karpouzas, Juan Tamargo, Alexander Niessner, Gianluigi Savarese, Giuseppe Rosano, Juan Carlos Kaski, Sven Wassmann, Pier Luigi Meroni, Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 2, April 2020, Pages 104–114 is available online at: https://doi.org/10.1093/ehjcvp/pvz033
Keywords: Rheumatoid arthritis, atherosclerosis, cardiovascular risk, inflammation, lipid management, statins
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur Heart J Cardiovasc Pharmacother
ISSN: 2055-6845
Language: eng
Dates:
DateEvent
April 2020Published
9 August 2019Published Online
30 July 2019Accepted
Publisher License: Publisher's own licence
PubMed ID: 31397840
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111070
Publisher's version: https://doi.org/10.1093/ehjcvp/pvz033

Actions (login required)

Edit Item Edit Item